DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People With Active Thyroid Eye Disease
Horizon Therapeutics plc today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium, and build upon data presented earlier this year that demonstrated the significant benefit of teprotumumab on proptosis (bulging eyes).
Teprotumumab is an investigational medicine for the treatment of active TED and is currently under review by the U.S. Food and Drug Administration (FDA). The teprotumumab Biologics License Application (BLA) was recently granted Priority Review by the FDA and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.
Evidence & EducationKnowledge of Thyroid Eye Disease in Graves’ Disease Patients With and Without OrbitopathyBackground: Thyroid eye disease (TED) d...
News & MeetingsWhat Causes Bulging Eyes?Having remarkably protruding eyes disrup...
Evidence & EducationThyroid Eye Disease: What is New to Know?Purpose of Review: The pathophysiology ...
Evidence & EducationComparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Acti...The intravenous methylprednisolone (iv M...
Evidence & EducationThyroid Eye DisordersWhat is the Thyroid? The thyroid is a b...
Evidence & EducationPREGO (Presentation of Graves’ Orbitopathy) Study: Changes in Referral Patterns to European Group On Graves...Background/Aims: The epidemiology of Gr...
Evidence & EducationQuality of Life and Neuropsychiatric Disorders in Patients With Graves’ Orbitopathy: Current ConceptsGraves' disease (GD) is an autoimmune ch...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.